Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials

BACKGROUND: Patients undergoing chemotherapy are known to be at risk for infection from myelosuppression by cytotoxic agents (CTAs) or immunosuppressive effects from mTOR inhibitors. The infection risk of newly developed anticancer agents has not been fully evaluated. It remains unknown how T-cell a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:ESMO Open
Main Authors: Fujiwara, Yutaka, Kuchiba, Aya, Koyama, Takafumi, Machida, Ryunosuke, Shimomura, Akihiko, Kitano, Shigehisa, Shimizu, Toshio, Yamamoto, Noboru
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Publishing Group 2020
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7174012/
https://ncbi.nlm.nih.gov/pubmed/32276948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000653
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker